CMML Prognostic Scoring Systems (from Spain and Dusseldorf)

Assess risk of progression to AML and early mortality in CMML


CMML is a stem cell disorder with heterogeneous clinical and pathologic features, often sharing characteristics of both myelodysplastic and myeloproliferative disorders. This study of 235 individuals registered in a German MDS Registry determined prognostic findings associated with overall survival and transformation to acute myeloid leukemia, specific to CMML. The authors identified 4 factors that were able to differentiate patients into 3 risk categories with expectant median survivals ranging from 11 months to 93 months. An alternative scoring system (from the Spanish Registry) is an option when cytogenetic studies are available.


Such E, Cervera J, Nomdedeu B, Pedro C, Bueno J, et al.

A New Prognostic Scoring System Including Transfusion Dependency and Cytogenetic Abnormalities for Patients with Chronic Myelomonocytic Leukemia. American Society of Hematology. New Orleans: Blood; 2009:abstract # 1750.

Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W.

Leukemia 1992, 6 (1): 52-9

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.

1. Blast Count?

0/4 completed